Superworth

Revolution Medicines EPS RVMD

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$8.84
Latest quarter, Q2 FY26
−$3.06
Fiscal year 2025
−$5.93

Revolution Medicines' earnings per share was −$8.84 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$3.06.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$5.93n/a
FY2024−$3.57n/a
FY2023−$3.77n/a
FY2022−$3.10n/a
FY2021−$2.56n/a
FY2020−$2.14n/a
FY2019−$22.23n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$3.06n/a−$8.84
Q1 FY26−$2.29n/a−$7.09
Q4 FY25−$1.88n/a−$5.93
Q3 FY25−$1.61n/a−$5.17
Q2 FY25−$1.31n/a−$4.50
Q1 FY25−$1.13n/a−$4.00
Q4 FY24−$1.12n/a−$3.57
Q3 FY24−$0.94n/a−$3.59
Q2 FY24−$0.81n/a−$3.64
Q1 FY24−$0.70n/a−$3.75
Q4 FY23−$1.14n/a−$3.77
Q3 FY23−$0.99n/a−$3.26

Against its peers

Companies in Biotechnology nearest Revolution Medicines' size, closest first, today.

CompanyEPS, 12 monthsGrowth
RVMDRevolution Medicines−$8.84
ONCBeOne Medicines$0.43
ALNYAlnylam Pharmaceuticals$5.93
UTHRUnited Therapeutics$27.95+9% a year
INCYIncyte$7.85+78% a year
REGNRegeneron Pharmaceuticals$40.44+2% a year
EXELExelixis$3.18+53% a year
NBIXNeurocrine Biosciences$6.82+102% a year
HALOHalozyme Therapeutics$3.35−23% a year
VRTXVertex Pharmaceuticals$17.18+23% a year
TECHBIO-TECHNE$1.15+150% a year
Peer median$6.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Revolution Medicines

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.